Seres Therapeutics to Present at the Baird 2017 Global Healthcare Conference
August 31 2017 - 7:05AM
Business Wire
Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will
present at the Baird 2017 Global Healthcare Conference in New York,
NY on Wednesday, September 6 at 10:50 a.m. ET.
A live audio webcast of the presentation will be available under
the “Investors and Media” section of Seres’ website. A replay of
the presentation will become available approximately one hour after
the event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., is a leading microbiome therapeutics
platform company developing a novel class of biological drugs that
are designed to treat disease by restoring the function of a
dysbiotic microbiome, where the natural state of bacterial
diversity and function is imbalanced. Seres’ lead program, SER-109,
has obtained Breakthrough and Orphan Drug designations from the
U.S. Food and Drug Administration and is in Phase 3 development for
multiply recurrent C. difficile infection. Seres’ clinical
candidate SER-287 is being evaluated in a Phase 1b study in
patients with mild-to-moderate ulcerative colitis. Seres is also
developing SER-262, the first ever synthetic microbiome therapeutic
candidate, in a Phase 1b study in patients with primary C.
difficile infection. For more information, please visit
www.serestherapeutics.com. Follow us on Twitter @SeresTx.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170831005275/en/
IR or PR Contact:Seres
Therapeutics,Carlo Tanzi, Ph.D., 617-203-3467Head of Investor
Relations and Corporate
Communicationsctanzi@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Sep 2023 to Sep 2024